128 related articles for article (PubMed ID: 18303433)
21. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
Hendriks LE; Derks JL; Postmus PE; Damhuis RA; Houben RM; Troost EG; Hochstenbag MM; Smit EF; Dingemans AM
Eur J Cancer; 2015 Nov; 51(17):2534-44. PubMed ID: 26323530
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
Kong FM; Frey KA; Quint LE; Ten Haken RK; Hayman JA; Kessler M; Chetty IJ; Normolle D; Eisbruch A; Lawrence TS
J Clin Oncol; 2007 Jul; 25(21):3116-23. PubMed ID: 17634490
[TBL] [Abstract][Full Text] [Related]
23. Metabolic tumor burden quantified on [
Lapa P; Oliveiros B; Marques M; Isidoro J; Alves FC; Costa JMN; Costa G; de Lima JP
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2169-2178. PubMed ID: 28785842
[TBL] [Abstract][Full Text] [Related]
24. Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer.
Changlai SP; Tsai SC; Chou MC; Ho YJ; Kao CH
Oncol Rep; 2001; 8(2):337-9. PubMed ID: 11182051
[TBL] [Abstract][Full Text] [Related]
25. Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer.
Vesselle H; Turcotte E; Wiens L; Haynor D
J Nucl Med; 2003 Dec; 44(12):1918-26. PubMed ID: 14660717
[TBL] [Abstract][Full Text] [Related]
26. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
[TBL] [Abstract][Full Text] [Related]
27. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
28. Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors.
Fried DV; Mawlawi O; Zhang L; Fave X; Zhou S; Ibbott G; Liao Z; Court LE
Radiology; 2016 Jan; 278(1):214-22. PubMed ID: 26176655
[TBL] [Abstract][Full Text] [Related]
29. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
[TBL] [Abstract][Full Text] [Related]
30. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study.
De Ruysscher D; Wanders S; van Haren E; Hochstenbag M; Geeraedts W; Utama I; Simons J; Dohmen J; Rhami A; Buell U; Thimister P; Snoep G; Boersma L; Verschueren T; van Baardwijk A; Minken A; Bentzen SM; Lambin P
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):988-94. PubMed ID: 15989999
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.
Chee KG; Nguyen DV; Brown M; Gandara DR; Wun T; Lara PN
Arch Intern Med; 2008 Jul; 168(14):1541-9. PubMed ID: 18663166
[TBL] [Abstract][Full Text] [Related]
32. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
33. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878
[TBL] [Abstract][Full Text] [Related]
34. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
35. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
Guan Y; He S; Dong J
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
[TBL] [Abstract][Full Text] [Related]
36. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer.
Dunagan D; Chin R; McCain T; Case L; Harkness B; Oaks T; Haponik E
Chest; 2001 Feb; 119(2):333-9. PubMed ID: 11171706
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.
Pillot G; Siegel BA; Govindan R
J Thorac Oncol; 2006 Feb; 1(2):152-9. PubMed ID: 17409845
[TBL] [Abstract][Full Text] [Related]
38. FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
Vansteenkiste JF
Lung Cancer; 2005 Feb; 47(2):151-3. PubMed ID: 15639713
[No Abstract] [Full Text] [Related]
39. Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma.
Su TP; Ho KC; Wang CW; Lin CY; Liu CY; Yang CT; Yen TC
Clin Nucl Med; 2019 Feb; 44(2):e68-e75. PubMed ID: 30608914
[TBL] [Abstract][Full Text] [Related]
40. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
